{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:42:26Z","timestamp":1769722946856,"version":"3.49.0"},"reference-count":12,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,5,20]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Acquired haemophilia A (AHA) is a rare and possibly fatal autoimmune disorder that is challenging to treat. Although a majority of cases are idiopathic, AHA can also be associated with an underlying malignancy, autoimmune disorder, pregnancy, infection or certain medications. The diagnosis and treatment of AHA require a specialist with both clinical and laboratory expertise. The goal of treatment is aimed at achieving haemostasis as well as eradicating factor inhibitors. We present a patient with AHA and life-threatening haemorrhage who was successfully treated with a combination of haemostatic agents and a triple-drug immunosuppressive regimen. In reviewing recent studies and published guidelines, we advocate that a newer agent, emicizumab, can potentially be incorporated into the treatment protocol for AHA given its promising performance in the realm of congenital haemophilia.<\/jats:p>","DOI":"10.1136\/bcr-2021-242876","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T12:13:07Z","timestamp":1624277587000},"page":"e242876","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Acquired haemophilia A: successful treatment of a patient using upfront immunosuppressive therapy and haemostatic agents"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04188639","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04188639","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6741-8741","authenticated-orcid":false,"given":"Su Yun","family":"Chung","sequence":"first","affiliation":[{"name":"Monter Cancer Center, Long Island Jewish Medical Center Northwell Health Cancer Institute, Lake Success, New York, USA"},{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Northwell Health, New Hyde Park, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice Gloria","family":"Shen","sequence":"additional","affiliation":[{"name":"Monter Cancer Center, Long Island Jewish Medical Center Northwell Health Cancer Institute, Lake Success, New York, USA"},{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Northwell Health, Manhasset, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin Lynn","family":"Sticco","sequence":"additional","affiliation":[{"name":"Pathology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"},{"name":"Department of Anatomic and Clinical Pathology, Northwell Health, Greenvale, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"2025082710105989000_14.6.e242876.1","first-page":"e5442","article-title":"Acquired hemophilia A: a rare but potentially fatal bleeding disorder","volume":"11","author":"Yousphi","year":"2019","journal-title":"Cureus"},{"key":"2025082710105989000_14.6.e242876.2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20390"},{"key":"2025082710105989000_14.6.e242876.3","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-3-161"},{"key":"2025082710105989000_14.6.e242876.4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001743"},{"key":"2025082710105989000_14.6.e242876.5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230771"},{"key":"2025082710105989000_14.6.e242876.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408930"},{"key":"2025082710105989000_14.6.e242876.7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650169","article-title":"A survey of 215 non-hemophilic patients with inhibitors to factor VIII","volume":"45","author":"Green","year":"1981","journal-title":"Thromb Haemost"},{"key":"2025082710105989000_14.6.e242876.8","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00277-020-04150-y","article-title":"Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study","volume":"99","author":"Dobbelstein","year":"2020","journal-title":"Ann Hematol"},{"key":"2025082710105989000_14.6.e242876.9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia a","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"2025082710105989000_14.6.e242876.10","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-Term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the Haven 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"2025082710105989000_14.6.e242876.11","unstructured":"Callaghan MU , Negrier CG , Paz-Priel I , et al . Paper: Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1\u20134) [Internet]. Available: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper137438.html [Accessed cited 2021 Feb 27]."},{"key":"2025082710105989000_14.6.e242876.12","unstructured":"Andreas Tiede . Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial [Internet]. clinicaltrials.gov, 2021. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04188639 [Accessed cited 2021 May 02]."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-242876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:11:09Z","timestamp":1756314669000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-242876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,21]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bcr-2021-242876"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-242876","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}